» Articles » PMID: 23554987

Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: a Multicenter Birth Cohort Study

Overview
Journal PLoS One
Date 2013 Apr 5
PMID 23554987
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study aimed to update and validate a prediction rule for respiratory syncytial virus (RSV) hospitalization in preterm infants 33-35 weeks gestational age (WGA).

Study Design: The RISK study consisted of 2 multicenter prospective birth cohorts in 41 hospitals. Risk factors were assessed at birth among healthy preterm infants 33-35 WGA. All hospitalizations for respiratory tract infection were screened for proven RSV infection by immunofluorescence or polymerase chain reaction. Multivariate logistic regression analysis was used to update an existing prediction model in the derivation cohort (n = 1,227). In the validation cohort (n = 1,194), predicted versus actual RSV hospitalization rates were compared to determine validity of the model.

Results: RSV hospitalization risk in both cohorts was comparable (5.7% versus 4.9%). In the derivation cohort, a prediction rule to determine probability of RSV hospitalization was developed using 4 predictors: family atopy (OR 1.9; 95%CI, 1.1-3.2), birth period (OR 2.6; 1.6-4.2), breastfeeding (OR 1.7; 1.0-2.7) and siblings or daycare attendance (OR 4.7; 1.7-13.1). The model showed good discrimination (c-statistic 0.703; 0.64-0.76, 0.702 after bootstrapping). External validation showed good discrimination and calibration (c-statistic 0.678; 0.61-0.74).

Conclusions: Our prospectively validated prediction rule identifies infants at increased RSV hospitalization risk, who may benefit from targeted preventive interventions. This prediction rule can facilitate country-specific, cost-effective use of RSV prophylaxis in late preterm infants.

Citing Articles

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.

Paes B, Lanari M, Rodgers-Gray B, Fullarton J, Carbonell-Estrany X Front Pediatr. 2024; 12:1343960.

PMID: 38283631 PMC: 10811053. DOI: 10.3389/fped.2024.1343960.


Impact of breastfeeding on the incidence and severity of respiratory syncytial virus (RSV)-associated acute lower respiratory infections in infants: a systematic review highlighting the global relevance of primary prevention.

Mineva G, Purtill H, Dunne C, Philip R BMJ Glob Health. 2023; 8(2).

PMID: 36746518 PMC: 9906265. DOI: 10.1136/bmjgh-2022-009693.


Comparison of the Canadian vs. the international risk scoring tool for respiratory syncytial virus prophylaxis in moderate-to-late preterm infants.

Butt M, Elliott L, Guy F, Symington A, Paes B Front Pediatr. 2023; 10:997349.

PMID: 36683806 PMC: 9851620. DOI: 10.3389/fped.2022.997349.


Machine learning early prediction of respiratory syncytial virus in pediatric hospitalized patients.

Tso C, Lam C, Calvert J, Mao Q Front Pediatr. 2022; 10:886212.

PMID: 35989982 PMC: 9385995. DOI: 10.3389/fped.2022.886212.


Identifying the Target Population for Primary Respiratory Syncytial Virus Two-Step Prevention in Infants: Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN).

Jourdain M, Benchaib M, Ploin D, Gillet Y, Javouhey E, Horvat C Vaccines (Basel). 2022; 10(5).

PMID: 35632484 PMC: 9147066. DOI: 10.3390/vaccines10050729.


References
1.
Boyce T, Mellen B, Mitchel Jr E, Wright P, Griffin M . Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000; 137(6):865-70. DOI: 10.1067/mpd.2000.110531. View

2.
Meissner H, Bocchini Jr J, Brady M, Hall C, Kimberlin D, Pickering L . The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics. 2009; 124(6):1676-9. DOI: 10.1542/peds.2009-2346. View

3.
Jansen A, Sanders E, Hoes A, van Loon A, Hak E . Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J. 2007; 30(6):1158-66. DOI: 10.1183/09031936.00034407. View

4.
Weisman L . Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Pediatr Infect Dis J. 2003; 22(2 Suppl):S33-7; discussion S37-9. DOI: 10.1097/01.inf.0000053883.08663.e5. View

5.
Lanctot K, Masoud S, Paes B, Tarride J, Chiu A, Hui C . The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis . Curr Med Res Opin. 2008; 24(11):3223-37. DOI: 10.1185/03007990802484234. View